We are thrilled to announce that CompagOs has been awarded an Innovation Cheque from the Swiss Innovation Agency Innosuisse. This significant support will enable us to kickstart the expansion of our capacity for scaling up the production of our Bon3OID™ models, in collaboration with the Swiss Center for Electronics and Microtechnology (CSEM).

This advancement will enhance our services with our biologically relevant 3D bioprinted in vitro bone models, allowing us to undertake more projects and produce more Bon3OID™ models for our customers. By providing robust, human-cell-based models, we aim to support researchers and pioneers in drug development, ensuring more accurate and reliable progress in the field of bone health.

Additionally, this expansion will facilitate our developmental efforts towards creating personalized diagnostics for early disease detection, allowing us to include a significant number of patients in our clinical trials and offer our solutions to a broader patient population. With more than 200 million patients worldwide suffering from bone metastases and osteoporosis, this support is crucial in addressing a major medical need.

We extend our sincere gratitude to Innosuisse and CSEM for their invaluable support.